Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ATR | Q13535 | 5/20 | 0.49 |
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462755 | 0.92 | ATR (0.51) | NPC1RAB9ASMN1; SMN2ATRPRKDC | |
| SCHEMBL3461443 | 0.90 | PIK3CD (0.57) | NPC1RAB9AATRPRKDCATM | |
| SCHEMBL3459736 | 0.81 | ATR (0.56) | ATRPRKDCATMPIK3CDPIK3CA | |
| SCHEMBL3460344 | 0.81 | PIK3CD (0.59) | NPC1RAB9ASMN1; SMN2ATRPRKDC | |
| SCHEMBL3460789 | 0.77 | PLK1 (0.50) | ATRPRKDCATMPIK3CDPIK3CA | |
| SCHEMBL3461072 | 0.75 | ATR (0.66) | NPC1RAB9AATRPRKDCATM | |
| SCHEMBL3461606 | 0.74 | ATR (0.55) | NPC1RAB9ASMN1; SMN2ATRPRKDC | |
| SCHEMBL3461135 | 0.74 | PIK3CD (0.47) | ATRPRKDCATMPIK3CDPIK3CA | |
| SCHEMBL3462777 | 0.74 | ATR (0.51) | NPC1RAB9ASMN1; SMN2ATRPRKDC | |
| SCHEMBL3461838 | 0.74 | ATR (0.55) | NPC1RAB9ASMN1; SMN2ATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | NPC1 4361/4885RAB9A 2909/4885SMN1; SMN2 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.